Inquiry Basket
Loading ......
Pasireotide represents a significant advancement in the treatment of endocrine disorders, functioning as a multi-receptor ligand analog of somatostatin. Unlike first-generation somatostatin analogs such as octreotide and lanreotide that predominantly target the somatostatin receptor subtype two, pasireotide demonstrates high binding affinity for multiple receptor subtypes, including somatostatin receptor one, two, three, and five. This broader binding profile translates into enhanced therapeutic efficacy, particularly for conditions where receptor subtype expression patterns differ from classical acromegaly. The mechanism of action centers on the inhibition of hormone secretion. Endogenous somatostatin, a cyclic peptide produced by the central nervous system, gastrointestinal tract, and pancreatic islets, naturally inhibits the release of growth hormone, corticotropin, and other hormones. Pasireotide mimics and amplifies these effects through its interaction with somatostatin receptors, which are G protein-coupled receptors widely expressed throughout the human body.
Figure 1.High Performance ELISA Kits for Pasireotide Pharmacokinetic and ADA Profiling.
| The Pathophysiology of Target Diseases | Details |
| Cushing's Disease | Cushing's disease represents a challenging endocrine disorder characterized by excessive adrenocorticotropic hormone production from a pituitary adenoma. This leads to supraphysiological cortisol levels from the adrenal glands, disrupting the normal circadian rhythm of cortisol secretion. The resulting hypercortisolism produces a constellation of debilitating symptoms including moon facies, buffalo hump, easy bruising, abdominal striae, obesity, facial plethora, and hirsutism.The molecular basis involves mutations such as USP8, leading to abnormal expression of growth factors that drive corticotroph adenoma formation. Importantly, corticotroph adenomas predominantly express somatostatin receptor subtype five, making pasireotide particularly effective as the first directed medical therapy for this condition. |
| Acromegaly | Acromegaly results from persistent growth hormone hypersecretion, nearly always from a pituitary adenoma, occurring after epiphyseal closure. The sustained growth hormone excess stimulates hepatic production of insulin-like growth factor one, which mediates most of the disease's systemic effects.Clinical manifestations include coarsening of facial features, prognathism, soft tissue swelling of hands and feet, hyperhidrosis, and deepening of the voice due to laryngeal cartilage proliferation. Internal organomegaly affects the heart, liver, kidneys, thyroid, and other organs. |
| Neuroendocrine Tumors | Neuroendocrine tumors represent a heterogeneous group of neoplasms arising from neuroendocrine cells throughout the body. Pasireotide's multi-receptor binding profile offers potential advantages in managing neuroendocrine tumors that may not respond adequately to first-generation analogs due to different receptor expression patterns. The anti-proliferative effects involve both direct receptor-mediated apoptosis and indirect antiangiogenic mechanisms. |
The clinical application of pasireotide necessitates rigorous monitoring through specialized analytical techniques. Pharmacokinetic profiling ensures appropriate drug exposure to achieve therapeutic efficacy while minimizing adverse effects. The high-performance enzyme-linked immunosorbent assay technology provides the sensitivity and specificity required for quantitative detection of pasireotide in biological matrices such as serum and plasma. Equally critical is the assessment of anti-drug antibodies. The development of immunogenicity against therapeutic proteins and peptides represents a significant clinical challenge. Anti-drug antibodies can neutralize drug activity, alter pharmacokinetics, and potentially cross-react with endogenous proteins, leading to adverse events. Monitoring anti-pasireotide antibodies enables early detection of immunogenicity, facilitating informed clinical decision-making and patient management.
Enzyme-linked immunosorbent assay methodology provides the analytical foundation for understanding pasireotide's clinical pharmacology. The sandwich ELISA format, utilizing specific antibodies that recognize distinct epitopes, enables precise quantification of both the drug and host immune responses. For pharmacokinetic applications, the pasireotide ELISA kit measures drug concentrations in circulation, supporting dose optimization studies, bioavailability assessments, and understanding of drug disposition. These data are essential for establishing pharmacokinetic-pharmacodynamic relationships and informing clinical dosing strategies. Immunogenicity assessment through the anti-pasireotide ELISA kit allows researchers to characterize the incidence and magnitude of anti-drug antibody formation. This information is crucial for evaluating the clinical significance of immunogenicity and developing strategies to mitigate its impact on treatment outcomes.
| ELISA Kits | Details |
| Anti-Pasireotide ELISA Kit | Pre-coated microplate; HRP-Conjugated Antibody; TMB Substrate; For Research Use Only |
| Pasireotide ELISA Kit | High sensitivity for pharmacokinetic studies; Suitable for therapeutic drug monitoring |
he availability of high-performance ELISA kits for pasireotide research supports the continued optimization of somatostatin analog therapy across multiple endocrine and oncological indications. Understanding drug exposure and immunogenicity profiles contributes to personalized treatment approaches, potentially improving outcomes for patients with Cushing's disease, acromegaly, and neuroendocrine tumors. As structural biology continues to reveal the molecular interactions between pasireotide and its receptor targets, with high-resolution cryo-electron microscopy structures now available showing distinct activation mechanisms , these analytical tools will facilitate translational research from bench to bedside. The insights gained from comprehensive pharmacokinetic and immunogenicity studies will guide the development of next-generation somatostatin analogs with enhanced efficacy and improved safety profiles. In summary, these specialized ELISA kits represent essential research tools for advancing our understanding of pasireotide pharmacology, supporting the clinical development and optimal use of this important therapeutic agent.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25289 | Anti-Pasireotide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25301 | Pasireotide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
